Advertisement

Topics

Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutic Agents

19:00 EST 31 Jan 2008 | NIH

Polymer matrix-based sustained-release formulations have gained significant interest in recent years for both parenteral and delivery of small molecules as well as proteins and other biological molecules. Compared to conventional dosage forms, these delivery systems offer improved efficacy, reduced toxicity, convenience and improved patient compliance. Colloidal carriers such as microparticles are considered a promising approach for targeting drugs to specific organs that could permit the sustained release at the target site and reduce potential side effects.

Matrix-structured microparticles that are formed by coacervation are desirable since they permit therapeutic agents to become incorporated into the microparticles under mild conditions (e.g. delivery of nucleic acids).

Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process, methods of forming the microparticles (with enhanced efficiency for microparticle sustained release compositions), and methods of using the microparticles for the sustained release administration of therapeutic agents (coacervate microparticles can be standardized and employed for the delivery of a variety of therapeutic agents).

IC: 
NIA
NIH Ref. No.: 
E-116-2004/0
TAB No: 
TAB-1105
Advantages: 
  • Enhanced efficacy of therapeutic agents
  • Reduced toxicity of therapeutic agents
  • Improved patient compliance
Applications: 
  • Hematology and oncology opportunities to develop sustained release or extended release formulations of chemotherapeutic drugs
  • Pain management
Provider Technology ID: 
1105
Updated On: 
Jun 29, 2017
Date Published: 
Friday, February 1, 2008
Provider Classifications: 
Publications: 
Patent Application: 
11/659,976
PCT/US2005/026257
60/602,651
Patent Authority: 
US
PCT
US
Patent Number: 
8,728,526
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NIA
LPM FIrst Name: 
Richard
LPM Last Name: 
Girards
LPM Address: 
BG 9609 RM 1E508 9609 MEDICAL CENTER DR
LPM City: 
Rockville
Inv Is lead: 
LPM Zip: 
20850-9702
LPM State: 
MD
LPM Phone: 
240-276-6825
LPM Suffix: 
J.D., M.B.A.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
240-276-5504
DTDT Classification: 
Infectious Diseases
Therapeutics
Other
Cancer
Cardiovascular Disease
Central Nervous System
Diabetes
Endocrine
Hyperlipidemia
Hypertension
Infectious Diseases (bacterial)
Pain
Psychiatry
Therapeutic (small molecule)
Early-stage
DTDT Description: 
Infectious Diseases
Infectious Diseases - Therapeutics
Infectious Diseases - Therapeutics: Other
Cancer
Cardiovascular Disease
Central Nervous System
Diabetes
Endocrine
Hyperlipidemia
Hypertension
Infectious Diseases (bacterial)
Pain
Psychiatry
Therapeutic (small molecule)
Early-stage
Pat Filing Date: 
2007-02-12
2005-07-25
2004-08-19
Patent Issue Date: 
2014-05-20
Application Term: 
Development Stage Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Researchers at the NIA seek licensing and/or co-development research collaborations.

E Number Only: 
E-116-2004
Inventor First Name: 
Phillip
Inventor Last Name: 
Heller

Original Article: Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutic Agents

NEXT ARTICLE

More From BioPortfolio on "Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutic Agents"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...